Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer (BC)-MedSci.cn

Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer (BC)

Meric-Bernstam, F; Krop, I; Juric, D; Kogawa, T; Hamilton, E; Spira, AI; Mukohara, T; Tsunoda, T; Damodaran, S; Greenberg, J; Gu, W; Kobayashi, F; Zebger-Gong, H; Kawasaki, Y; Wong, R; Bardia, A

CANCER RESEARCH, 2023; 83 (5):

科室
- - 订阅+
  - 更多科室
工具
服务